Comparison of extended intervals and dose reduction of omalizumab for asthma control
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2197-0378
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparison of extended intervals and dose reduction of omalizumab for asthma control ; volume:28 ; number:1 ; day:14 ; month:12 ; year:2018 ; pages:1-4 ; date:2.2019
Allergo journal international ; 28, Heft 1 (14.12.2018), 1-4, 2.2019
- Creator
-
Bölke, Georg
Church, Martin K.
Bergmann, Karl-Christian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40629-018-0087-6
- URN
-
urn:nbn:de:101:1-2019030323520074360949
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bölke, Georg
- Church, Martin K.
- Bergmann, Karl-Christian
- SpringerLink (Online service)
Other Objects (12)
Severe asthma and the omalizumab option
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
Omalizumab bei Kinderurtikaria
"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma
Disease-Modifikation und Dauer einer Omalizumab-Therapie bei Patienten mit schwerem allergischen Asthma
Severe asthma and the omalizumab option
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
Omalizumab bei Kinderurtikaria
"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma
Disease-Modifikation und Dauer einer Omalizumab-Therapie bei Patienten mit schwerem allergischen Asthma
Severe asthma and the omalizumab option
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
Omalizumab bei Kinderurtikaria
"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma